Merck & Co., Inc. (MRK)
NYSE: MRK · IEX Real-Time Price · USD
125.26
-0.59 (-0.47%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Merck & Co. Employees
Merck & Co. had 72,000 employees as of December 31, 2023. The number of employees increased by 3,000 or 4.35% compared to the previous year.
Employees
72,000
Change (1Y)
3,000
Growth (1Y)
4.35%
Revenue / Employee
$852,806
Profits / Employee
$32,028
Market Cap
317.26B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
Dec 31, 2018 | 69,000 | 0 | - |
Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
Dec 31, 2016 | 68,000 | 0 | - |
Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
MRK News
- 8 hours ago - Germany's Merck raises 2024 sales forecast - Reuters
- 13 hours ago - Is An Earnings Beat In The Cards For Merck Stock? - Forbes
- 14 hours ago - Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma - Business Wire
- 3 days ago - Merck Announces Fourth-Quarter 2024 Dividend - Business Wire
- 3 days ago - Merck's RSV drug meets main goals of mid-to-late stage trial - Reuters
- 3 days ago - Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants - Business Wire
- 10 days ago - Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024 - Business Wire
- 10 days ago - Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing - GlobeNewsWire